Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 7
Considerations for Use of CAR T-cell Therapy in Multiple Myeloma
Panelists discuss how patient and disease factors influence the choice between ide-cel and cilta-cel for chimeric antigen receptor (CAR) T-cell therapy, the significance of adverse event profiles in clinical decision-making, the use of bridging therapy prior to infusion, and the experiences of progression rates and potential mechanisms post treatment, as well as future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma.
- Dr Ajai Chari to Dr Rossi (then open to panelists): What patient or disease factors do you weigh when deciding whether a patient should receive ide-cel vs cilta-cel?
- Dr Ajai Chari to Dr Martin: When weighing treatment options, how heavily is the chimeric antigen receptor (CAR) T adverse effect (AE) profile considered in your clinical judgment?
- What are the similarities and differences between the AE profiles of ide-cel vs cilta-cel?
- Dr Ajai Chari to Dr Callander: What is your approach to bridging therapy prior to CAR T-cells being infused?
- How frequently do you utilize bridging therapy? What agents are you typically using?
- Dr Ajai Chari to Dr Raje: Of the patients you have treated with CAR T-cell therapy, what percentage of patients have progressed?
- How long until progression occurs in your experience?
- What are some possible mechanisms of release post CAR T-cell therapy?
- Dr Ajai Chari to Dr Rossi: What are some future directions for CAR T-cell therapy in relapsed/refractory multiple myeloma?
Related Content:
